Alnylam Pharmaceuticals, Inc. (LON:0HD2)
317.45
-4.19 (-1.30%)
At close: Jul 1, 2025
Alnylam Pharmaceuticals Employees
Alnylam Pharmaceuticals had 2,230 employees as of December 31, 2024. The number of employees increased by 130 or 6.19% compared to the previous year.
Employees
2,230
Change (1Y)
130
Growth (1Y)
6.19%
Revenue / Employee
814.98K GBP
Profits / Employee
-93.61K GBP
Market Cap
31.03B
Employees Chart
Employees History
Related Stocks
Company Name | Employees |
---|---|
AstraZeneca | 94,300 |
GSK plc | 68,629 |
Haleon | 24,561 |
Smith & Nephew | 17,349 |
ConvaTec Group | 10,489 |
Hikma Pharmaceuticals | 9,500 |
HUTCHMED (China) | 1,811 |
Genus | 3,500 |
Alnylam Pharmaceuticals News
- 6 hours ago - Alnylam Pharma Stock Outlook: Is ALNY Topping Out? - Benzinga
- 6 hours ago - Alnylam Pharma Stock Outlook: Is ALNY Topping Out? - Benzinga
- 13 days ago - Alnylam Pharmaceuticals Names Garg R&D Chief - Market Watch
- 13 days ago - Alnylam Announces Promotion of Pushkal Garg to Chief Research and Development Officer - Business Wire
- 22 days ago - Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy - Business Wire
- 26 days ago - Moderna Beats Alnylam Appeal In COVID Vaccine Patent Case - Benzinga
- 4 weeks ago - Why Alnylam Could Outperform In The Transthyretin Amyloidosis With Cardiomyopathy Field - Seeking Alpha
- 4 weeks ago - Alnylam to Webcast Presentation at Goldman Sachs 46th Annual Global Healthcare Conference - Business Wire